Vensana Capital

Vensana Capital is a Minneapolis-based venture and growth equity firm founded in 2019 by Kirk Nielsen and Justin Klein, two veterans of the medtech industry with deep roots in the Upper Midwest's unmatched medical technology cluster Understanding healthcare financial benchmarks helps founders navigate this. In just six years, the firm has amassed approximately $1 billion in assets under management across three funds — Fund I at roughly $250M, Fund II at $325M (closed September 2021), and Fund III at $425M (closed January 2025). The firm operates from offices in Minneapolis and Washington, D.C., leveraging proximity to Medtronic's campus and the broader Great Lakes medtech ecosystem.

What sets Vensana apart is the firm's operational intensity. Nielsen and Klein spent years inside medtech companies before launching their own fund, and that operator experience shapes how the firm works with founders. Vensana does not take a passive board seat approach — the team is deeply involved in regulatory strategy, reimbursement planning, clinical trial design, and commercialization paths for each portfolio company. This is not a firm that writes a check and waits for an exit.

The numbers tell a compelling story: across its portfolio, Vensana-backed companies have achieved 22 novel FDA PMA and De Novo 510(k) approvals, 61 U.S. commercial product launches, and 32 exits via IPO or strategic M&A. These are not vanity metrics — they reflect a firm that selects for companies ready to execute at commercial stage, not just companies with promising preclinical data.

For founders seeking growth-stage capital in medtech, Vensana Capital represents a specific type of partner: one with the sector depth to add strategic value, the capital to write meaningful checks ($30M–$35M average investment per company), and the network to open doors at health systems, IDNs, and strategic acquirers across the medtech landscape.

Vensana Capital's investment thesis is anchored in a single belief: medtech innovation can simultaneously improve clinical outcomes and reduce overall healthcare costs, and the best returns come from companies that fundamentally reshape how a condition is treated rather than iterating on existing approaches. The firm explicitly targets entrepreneurs who are pioneering new treatments for chronic diseases, building entirely new commercial markets from scratch, and advancing personalized medicine and connected care platforms. Understanding cash conversion cycles in healthcare is valuable for any founder.

The firm invests across the medtech spectrum — medical devices, diagnostics, digital health, and therapeutic platforms — but always with an emphasis on companies that have achieved or are rapidly approaching human clinical data and regulatory clearance. Vensana is not an early-stage seed investor; the firm prefers to see proof of mechanism, initial safety data, and a clear regulatory pathway before writing a growth-stage check. Their sweet spot is companies with $5M–$30M in revenue or companies that have demonstrated strong single-arm clinical data heading into a pivotal trial.

Vensana's geographic concentration in Minneapolis is not accidental. The Upper Midwest medtech cluster — anchored by Medtronic but also including hundreds of supplier firms, contract manufacturers, and seasoned medtech operators — gives portfolio companies natural access to talent, prototyping resources, and strategic partnerships that founders in other markets simply cannot replicate as easily. The firm leverages this ecosystem actively for its portfolio.

Vensana Capital closed its third fund in January 2025, raising $425 million — oversubscribed at its hard cap — demonstrating limited partner confidence in the firm's ability to source and support transformative medtech companies even in a challenging capital markets environment. In the six years since launch, the firm has deployed roughly $1 billion across 34 strategic financings, making it one of the most active growth-stage medtech investors in the United States.

Recent portfolio activity reflects the firm's conviction in several emerging medtech categories. The firm led Okami Medical's $32.5M financing in October 2024 and followed that with a subsequent $45M round in November 2025. Vensana has also been active in nerve ablation (Relievant Medsystems, sold to Boston Scientific for up to $850M), interventional cardiology (Cleerly), and wireless implantables (Fire1). The firm's portfolio page lists 16 active companies across cardiac, neural, diabetes, and diagnostic applications.

The firm maintains a deliberate pace: Vensana does not chase deal volume. Instead, the team focuses on a smaller number of meaningful positions where their operational experience can meaningfully move the needle. This selectivity has been a hallmark of the firm's approach since its founding, even as AUM has grown from Fund I to Fund III.

Market conditions in medtech venture have been bumpy — device exits took a hit in 2022–2023 as rate sensitivity compressed multiples — but Vensana's portfolio has held up relatively well. The firm exits have included major strategic M&A at favorable valuations (Cameron Health to Boston Scientific, Vertiflex to Boston Scientific, CardiAQ to Edwards Lifesciences) and two public market IPOs in CVRx and Inari Medical.

Vensana's active portfolio is concentrated in mid-to-late-stage medical technology companies with clear clinical and regulatory milestones ahead of them. Key active holdings include Alleviant (interventional heart failure), Apella (healthcare technology systems), Cleerly (cardiac imaging AI), Elucent Medical (surgical guidance), Fire1 (congestive heart failure monitoring), iVEAcare (neuromodulation), Okami Medical (neurovascular embolization), Rampart IC (infection prevention), and Ventaris Surgical (women's health).

On the exit side, Vensana's track record is notable. CVRx went public on NASDAQ in 2021 (ticker: CVRX), offering a neuromodulation device for heart failure that the firm had backed through multiple rounds. Inari Medical went public in 2021 (NASDAQ: NARI) with a thrombectomy platform and traded at a significant premium. Cameron Health was acquired by Boston Scientific for $1.4B plus contingencies. Vertiflex was acquired by Boston Scientific for $450M upfront. These are the outcomes that define a medtech VC's reputation.

Vensana also launched Vensana Innovation (VI), a separate initiative focused on earlier-stage opportunities and founder partnerships that complement the main fund's growth equity strategy. This gives the firm flexibility to engage with entrepreneurs at slightly earlier stages without forcing them into the main fund's commercial-stage mandate.

Vensana evaluates potential investments on four dimensions: clinical differentiation, regulatory pathway clarity, commercial readiness, and team depth. The firm is looking for companies whose technology represents a meaningful leap over existing standard of care, not incremental improvements. A company needs a clear FDA regulatory pathway — ideally with an approved protocol or IDE in place — and a reimbursement strategy that has been thought through, not left for post-approval scrambling.

On the commercial side, Vensana wants to see evidence of physician adoption, initial sales traction, or at minimum a compelling distribution model that gives the company a credible path to revenue. The firm is particularly interested in companies with procedures that can be standardized and taught quickly — platforms that require years of specialist training to adopt are structurally disadvantaged in Vensana's view.

Team quality matters enormously. Vensana prefers founders with prior medtech scaling experience — people who have navigated a 510(k) or PMA before, built a commercial team, or worked through reimbursement coding cycles. The firm has seen thousands of pitches and can quickly distinguish between founders who understand the realities of hospital procurement and reimbursement versus those building primarily on a technical insight.

Vensana also evaluates competitive positioning carefully. The firm wants to see moats — whether those are patent estates, exclusive supplier relationships, first-mover advantage in a new treatment category, or proprietary clinical data that generates guideline inclusion. A company needs a defensible market position, not just a good idea.

Finally, Vensana looks for capital efficiency. The firm wants to understand how the current round fits into the company's broader financial plan — how far does the capital get the company in terms of clinical milestones, regulatory submissions, or commercial scale? Founders who have thought carefully about their path to breakeven or the next priced round, rather than those simply raising to extend runway, stand out in the process.

The most reliable path to Vensana Capital is a warm introduction from someone in the medtech ecosystem that the firm knows and trusts — a portfolio CEO, a medtech executive advisor in the Vensana network, a strategic partner, or a co-investor with whom the firm has an established relationship. Given the firm's small deal volume and deep sector focus, reputation and trust matter enormously before a first meeting is scheduled.

The firm does accept inbound inquiries through its website at vensanacap.com, and the team reviews every submission. However, cold inbound volume is high, so a concise, specific pitch that directly addresses Vensana's investment thesis — rather than a generic deck forwarded to every VC in the sector — has a meaningfully better chance of landing a meeting. Lead with clinical differentiation, regulatory status, and why your market is large enough to support a category-defining company.

When you do get a meeting, come prepared. Vensana's partners will ask hard questions about your FDA regulatory pathway, your reimbursement strategy, your clinical trial design, and your assumptions about competitive response from established medtech giants. The due diligence process for medtech investments is typically 4–8 weeks and includes deep clinical review, regulatory analysis, and market assessment. Do not walk in with polished slides and unprepared answers on clinical data.

Follow-up discipline matters. Vensana typically takes several weeks to make an investment decision after a first meeting, and the firm's partners are managing an active portfolio alongside deal evaluation. Send milestone updates without being pushy — meaningful clinical or regulatory progress is the most compelling update you can send. Even if the current round does not result in a term sheet, maintaining a relationship with Vensana can be valuable for future rounds as your company advances.

Medtech is an expensive category to fund. Pivotal clinical trials, FDA submission fees, quality management systems, and the漫长的 reimbursement negotiation process mean that medtech companies typically need more capital per dollar of revenue than software businesses. Vensana Capital's $30M–$35M average investment reflects this reality — the firm is looking for companies that need meaningful capital to reach the next value inflection point, whether that is a pivotal trial readout, an FDA approval, or commercial scale.

For founders, this means that financial preparedness is not optional when pitching Vensana. The firm wants to see that you understand your burn rate, your cash runway relative to key milestones, and your unit economics at such time as you have revenue. For pre-revenue companies, that means a detailed clinical trial budget and a clear understanding of how much additional capital you will need post-approval to build a commercial organization.

Working with a fractional CFO who understands medtech fundraising can be the difference between a meeting and a term sheet. Investors in this sector expect financial models that account for the actual cost and timeline of clinical development, not compressed software-style growth projections. A fractional CFO can help you build investor-ready projections, prepare for the财务 due diligence that follows a term sheet, and anticipate the questions Vensana's partners will ask about your capital structure and milestones.

Whether you are preparing for a Vensana Capital pitch or evaluating other medtech-focused growth investors, professional financial infrastructure sets your company apart from the competition. Medtech fundraising is a different beast than software — the due diligence is more intensive, the timelines are longer, and the investors are more skeptical of hockey-stick projections that ignore the genuine costs of clinical development and reimbursement. Get the fundamentals right before you walk into a room full of former medtech operators.

Exploring other venture capital firms? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and tips for securing funding. Whether you are looking for seed-stage investors or growth equity firms, you will find valuable insights in our VC firm guides.

Finding the right investor for your startup is crucial to your success. Take the time to research potential investors and understand their investment thesis before reaching out.

Our guides cover major venture capital firms as well as emerging managers that may be a better fit for your company's specific needs and stage.